No description available.

No description available.

No description available.

Die dreidimensionale Organisation des Chromatins verändert sich während der Zelldifferenzierung als Reaktion auf die Umgebung und ist bei Krankheiten oftmals verändert. Das Zusammenspiel zwischen Chromatinzustand, Chromatinorganisation und Genexpression ist insbesondere bei Neuronen nach wie vor nur geringfügig erforscht. In dieser Arbeit untersuchte ich die Organisation und den Zustand des Chromatins im Zusammenhang mit der Transkription in embryonalen Stammzellen (ESCs) und dopaminergen Neuronen (DNs) der Maus. Dazu habe ich die Organisation des Chromatins mittels Genome Architecture Mapping (GAM) bestimmt und zelltypspezifische Genexpressionsprofile zur Klassifizierungen von Promotoren, Enhancern und Super-Enhancern (SEs) erzeugt. Anschließend habe ich diese linearen Chromatinprofile mit den verschiedenen Stufen der Chromatinorganisation kombiniert und konnte so Unterschiede zwischen den 3D-Genomstrukturen von ESCs und DNs aufzeigen. Zudem konnte ich verstärkt Dreifach-Wechselwirkungen zwischen zelltypspezifischen SEs und/oder exprimierten Genen nachweisen, die bei DNs besonders oft neuronale Signalgene darstellen und oftmals bei neurologischen Störungen betroffen sind. Ich fand auch heraus, dass die Grenzen topologisch assoziierter Domänen (TADs) oft mit Genen zur zellulären Differenzierung zusammen fallen und zudem zelltyp-spezifische Eigenschaften aufweisen, was von Bedeutung für zukünftige funktionelle Untersuchungen solcher Grenzen sein dürfte. Schließlich konnte ich zeigen, dass Chromatinkompartimente zwischen ESCs und DNs in Abhängigkeit vom Chromatinzustands und der Chromatinexpression variieren und dass eine Gruppe transkriptionell aktiver DN Gene, die für die neuronale Aktivität wichtig sind, in B-Kompartimenten liegt. Mit diesen neuen Erkenntnissen erweitert meine Arbeit das Verständnis der Chromatinorganisation bei der Regulierung der Genexpression in Maus ESCs und DNs. / The three-dimensional organization of chromatin changes during cell differentiation, in response to the environment, and is often altered in disease. The interplay between chromatin state, chromatin organization and gene expression remains poorly understood, particularly in neurons. In this work, I examined the organization and state of chromatin associated with transcription in mouse embryonic stem cells (ESCs) and dopaminergic neurons (DNs). To do this, I determined the organization of chromatin using genome architecture mapping (GAM) and generated cell type-specific gene expression profiles to classify promoters, enhancers and super-enhancers (SEs). I then combined these linear chromatin profiles with the different levels of chromatin organization and was able to show differences between the 3D genome structures of ESCs and DNs. In addition, I was able to demonstrate increased triple interactions between cell type-specific SEs and/or expressed genes, which are often neuronal signalling genes in DNs and affected in neurological disorders. I also found that the boundaries of topologically associated domains (TADs) often coincide with cellular differentiation genes and also exhibit cell type-specific properties, which may be important for future functional studies of such boundaries. Finally, I was able to show that chromatin compartments between ESCs and DNs vary depending on chromatin state and chromatin expression, and that a group of transcriptionally active DN genes important for neuronal activity are located in B compartments. With these new findings, my work expands the understanding of chromatin organization in regulating gene expression in mouse ESCs and DNs.

Indiana University-Purdue University Indianapolis (IUPUI) / Endothelial Colony Forming Cells (ECFCs) are highly proliferative endothelial progenitor cells with clonal proliferative potential and in vivo vessel forming ability. While endothelial cells have been derived from human induced pluripotent stem cells (hiPS) or human embryonic stem cells (hES), they are not highly proliferative and require ectopic expression of a TGFβ inhibitor to restrict plasticity. Neuropilin-1 (NRP-1) has been reported to identify the emergence of endothelial precursor cells from human and mouse ES cells undergoing endothelial differentiation. However, the protocol used in that study was not well defined, used uncharacterized neuronal induction reagents in the culture medium, and failed to fully characterize the endothelial cells derived. We hypothesize that NRP-1 expression is critical for the emergence of stable endothelial cells with ECFC properties from hES cells. We developed a novel serum and feeder free defined endothelial differentiation protocol to induce stable endothelial cells possessing cells with cord blood ECFC-like properties from hES cells. We have shown that Day 12 hES cell-derived endothelial cells express the endothelial markers CD31+ NRP-1+, exhibit high proliferative potential at a single cell level, and display robust in vivo vessel forming ability similar to that of cord blood-derived ECFCs. The efficient production of the ECFCs from hES cells is 6 logs higher with this protocol than any previously published method. These results demonstrate progress towards differentiating ECFC from hES and may provide patients with stable autologous cells capable of repairing injured, dysfunctional, or senescent vasculature if these findings can be repeated with hiPS.

No description available.

No description available.

The development of safe and efficient gene delivery systems in pluripotent human embryonic stem cells (hESc) is essential to realising their full potential for basic and clinical research. The purpose of this study was to develop an efficient, non-integrating gene expression system in pluripotent hESc using human artificial chromosomes (HAC). Similar to endogenous chromosomes, HAC are capable of gene expression, replication and segregation during cell division. Unlike retroviral-mediated gene delivery vectors, HAC do not integrate into the host genome and can encompass large genomic regions for the delivery of multiple genes. Despite the advantages HAC offer, their use has been limited due to laborious cloning procedures and poor transfection efficiencies, and thus only studied in immortalised and tumour-derived human cell lines. In this study, the high transduction efficiency of herpes simplex virus type-1 (HSV-1) amplicons was utilised to overcome the described difficulties and delivered HAC vectors into pluripotent hESc. Analysis of stable hESc clones showed that de novo gene-expressing HAC were present at high frequencies ranging from 10-70% of metaphases analysed, without integrating into the genome. The established HAC contained an active centromere, and were stably maintained without integration or loss in the absence of selection for 90 days. Stable HAC-containing hESc clones retained their pluripotency as demonstrated by neuronal differentiation, in vitro germ layer and teratoma formation assays. HAC gene expression persisted, with some variation, post-differentiation in the various deriving cell types. This is the first report of successful de novo HAC formation in hESc for gene expression studies. These findings show potential for delivering high-capacity genomic constructs safely and efficiently into pluripotent cells for the purpose of genetic manipulation and ultimately patient-specific somatic gene therapy.

Development of safe and efficient approaches for gene delivery in human embryonic stem cells (hESc) and particularly in human induced pluripotent stem (hiPS) cells, which can be derived in a person-specific manner, is considered to be imperative for harnessing their full potential in both the basic and applied research. The aim of this study was to evaluate the potential of human artificial chromosome (HAC) for gene delivery and expression in hESc and hiPS cells. HAC offers many potential advantages including the provision for carrying large genes with corresponding regulatory elements to obtain long-term regulated gene expression. In addition, they can replicate and segregate independently without integration into the host cell genome. To develop HAC in hiPS cells, the first part of the study was aimed at generating hiPS cells utilising the Herpes Simplex Virus (HSV)-1 amplicon system. With the use of EBNA-1/OriP retention elements incorporated into the HSV-1 amplicon vectors, hiPS cells completely free of vector and transgenes sequences were successfully derived from human embryonic fibroblasts. The hiPS cells exhibited proliferation and differentiation potential similar to that of hESc. In the second part of the study, development of HAC in hESc and hiPS cells was assessed by utilising the HSV-1 amplicon system to deliver the HAC DNA. Analysis of the hESc confirmed the presence of functional HAC which replicated the behaviour of the host chromosomes. Additionally, HAC generation did not lead to impairment in the developmental potential and pluripotency of hESc. The hiPS cells supported HAC at low frequency but DNA also integrated into the host chromosomes. The HAC system, therefore, needs further refinements to improve the frequency of HAC formation and reduce the chromosomal integration of HAC constructs in hiPS cells. Overall, these findings provide a simple and safe way of pluripotency induction and genetic modification of pluripotent stem cells using the HSV-1 amplicon system and represent an important advance towards patient specific gene and cell therapy.

"Mémoire présenté à la Faculté des études supérieures en vue de l'obtention du grade de Maîtrise en droit (L.L.M.) Option recherche" / La découverte des cellules souches embryonnaires et de leur immense potentiel thérapeutique a fait naître de grands espoirs. De nouvelles thérapies révolutionnaires pour traiter certaines des maladies les plus graves dont souffre l'humanité sont désormais envisageables. Le traitement de la vie à son stade le plus précoce est mis en cause. Le statut juridique reconnu au foetus et à l'embryon humain a des répercussions directes sur le domaine de la recherche et sur leur utilisation à des fins thérapeutiques. Nous avons examiné l'état du droit canadien quant au statut juridique du foetus et de l'embryon. De cette étude, nous avons constaté l'incertitude qui prévaut au Canada quant à leur statut. Par la suite, nous avons étudié les différentes normes canadiennes établies pour encadrer l'utilisation des cellules souches embryonnaires à des fins thérapeutiques et nous les avons analysées et comparées pour faire ressortir leurs similitudes et leurs différences. II est ressorti de notre analyse que les textes canadiens se rejoignent généralement sur l'essentiel et qu'il y a eu peu de changements de 1993 à aujourd'hui, en regard des activités de recherche interdites au Canada. Puis, nous avons examiné les systèmes normatifs applicables à ces recherches à l'étranger, soit aux États-Unis et en GrandeBretagne. Nous avons effectué une analyse comparative des trois systèmes normatifs étudiés, en évaluant différents paramètres communs à ces systèmes. Il est ressorti de cette analyse, que la Grande-Bretagne est le pays le plus libéral relativement à ces domaines de recherche, que les États-Unis sont les plus conservateurs sur ces questions et que le Canada se situe entre les deux. / The embryonic stem cells discovery and the immense therapeutic potential glven to them has created big hopes in the world of today. The appearance of new revolutionary therapies to treat sorne of the most serious known diseases are now conceivable. However, the treatment of life to its earliest stage is questionned. The legal status recognized to the foetus and the embryo has, in fact, a direct effect to the research area and industry as weil as to its therapeutic use. Therefore, we have examined and studied the CUITent canadian law with respect to the legal status of the foetus and embryo. Following this study, we have noticed the uncertainty that prevails in Canada concerning the said legal status. Afierwards, we have examined ail the different canadian norms and regulations already established regarding the use of embryonic stem cells for therapeutic ends. We also did the comparaison between those norms and regulations so as to see their differences and similarities. It appears from our analysis that ail the canadian litterature generally treat the subject in the same way and that there have been few changes from 1993 up until now with respect to the forbidden researchs activities in Canada. We also have analysed the foreign law standards and regulations in United States and Great Britain concerning those forbidden researchs activities. We did the exercise of comparing the state of the law in these three countries with different parameters. It emerges from that that Great Britain is the most liberal country, United States being the most conservative and Canada being in between them.